WVE · Wave Life Sciences, Inc. · Executive Compensation
$3.93
+0.23 (+6.19%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$744.84M
Shares
197.05M
Volume · Oct 1
2.4M
Avg daily vol (3M)
3.05M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Paul Bolno | M.D., MBA President and Chief Executive Officer | $4,272,299 |
| Kyle Moran | Chief Financial Officer | $1,917,381 |
| Chandra Vargeese | Chief Technology Officer, Head of Platform Discovery Sciences | $1,888,563 |
| Christopher Francis | Senior Vice President, Corporate Development and Head of Emerging Areas | $1,566,422 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Paul Bolno | M.D., MBA President and Chief Executive Officer | $3,874,300 |
| Chandra Vargeese | Chief Technology Officer, Head of Platform Discovery Sciences | $1,783,339 |
| Kyle Moran | Chief Financial Officer | $1,697,072 |
| Christopher Francis | Senior Vice President, Corporate Development and Head of Emerging Areas | $1,527,469 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Paul Bolno | M.D., MBA President and Chief Executive Officer | $2,667,997 |
| Chandra Vargeese | Chief Technology Officer, Head of Platform Discovery Sciences | $1,231,794 |
| Kyle Moran | Chief Financial Officer | $1,148,790 |
| Christopher Francis | Senior Vice President, Corporate Development and Head of Emerging Areas | $1,010,645 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Anne-Marie Li-Kwai-Cheung | Chief Development Officer | Appointed | 2022-09-26 |
| Michael Panzara, M.D., MPH | Chief Medical Officer, Head of Therapeutics Discovery and Development | Resigned | 2022-09-26 |